首页> 外文期刊>Nanotechnology research journal >Nanoparticle for Ocular Drug Delivery: What We Have Today?
【24h】

Nanoparticle for Ocular Drug Delivery: What We Have Today?

机译:用于眼部药物递送的纳米颗粒:我们今天拥有什么?

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Nanotechnology has evolved in a big way in the area of nanodrug delivery. The present paper focuses on scientific basis, methods and applications of available nanoparticles and nanodrugs for ocular drug delivery. Nanotechnology has opened the vistas of cheaper, economical, easy deliverables to meet challenges of conventional ocular drug delivery in past. Still today, science of nanotechnology in ophthalmic use is in its infancy.In last decade, FDAapproved only 21 conventional ocular drugs while 30 new nondrugswere approved since the year 1995. It is today a matter of eye-catching attention that the recently proved efficiency of nanoparticles for ocular drug delivery is far better than old conventional drug delivery systems in terms of dose, stability, cell targeting, particle size etc. The present evidences as review on the nanoparticles for ocular delivery methods related to drug entrapment, method of manufacturing, toxicity and drug regulatory control.
机译:纳米技术在纳米药物递送领域已经有了很大的发展。本文着重于眼科药物递送的可用纳米颗粒和纳米药物的科学基础,方法和应用。纳米技术已经打开了廉价,经济,易于交付的前景,以应对过去传统眼药交付的挑战。时至今日,纳米技术在眼科领域的应用还处于起步阶段。在过去的十年中,FDA自1995年以来仅批准了21种常规眼用药物,而批准了30种新的非药物。就剂量,稳定性,细胞靶向性,粒径等方面而言,用于眼用药物递送的纳米颗粒远远优于旧的传统药物递送系统。目前的证据是与药物包埋,制造方法,毒性有关的眼用递送纳米颗粒的方法综述和药品监管控制。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号